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Background: Ventilator-associated pneumonia (VAP) accounts for 25% of infections in intensive care units.
Compared to a long duration (LD) of antibiotic therapy, a short duration (SD) has a comparable clinical efficacy with
less antibiotic use and less multidrug-resistant (MDR) pathogen emergence, with the exception of documented VAP
of non-fermenting Gram-negative bacilli (NF-GNB), including Pseudomonas aeruginosa (PA). These results have led
the American Thoracic Society to recommend SD therapy for VAP, except for PA-VAP. Thus the beneficial effect of
SD therapy in PA-VAP is still a matter of debate. We aimed to assess the non-inferiority of a short duration of
antibiotics (8 days) versus prolonged antibiotic therapy (15 days) in PA-VAP.
Methods/design: The impact of the duration of antibiotics on clinical events in patients with Pseudomonas
aeruginosa ventilator-associated pneumonia (iDIAPASON) trial is a randomized, open-labeled non-inferiority
controlled trial, conducted in 34 French intensive care units (ICUs), comparing two groups of patients with PA-VAP
according to the duration (8 days or 15 days) of effective antibiotic therapy against PA. The primary outcome is a
composite endpoint combining day 90 mortality and PA-VAP recurrence rate during hospitalization in the ICU.
Furthermore, durations of mechanical ventilation and hospitalization, as well as number and types of
extrapulmonary infections or acquisition of MDR pathogens during the hospitalization in the ICU will be recorded.
Recurrence with predefined criteria (clinical suspicion of VAP associated with a positive quantitative culture of a
respiratory sample) will be evaluated by two independent experts.
Discussion: Demonstrating that an SD (8 days) versus LD (15 days) therapy strategy in PA-VAP treatment is safe and
not associated with an increased mortality or recurrence rate could lead to a change in practices and guidelines in the
management of antibiotic therapy of this frequent ICU complication. This strategy could lead to decreased antibiotic
exposure during hospitalization in the ICU and in turn reduce the acquisition and the spread of MDR pathogens.
Trial registration: ClinicalTrials.gov: NCT02634411. Registered on 19 November 2015.
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Ventilator-associated pneumonia (VAP) is a major cause
of morbidity and mortality in intensive care units
(ICUs), accounting for 25% of infections in these units
[1]. From 1975 to 2003, the incidence of hospital-
acquired pneumonia caused by Pseudomonas aeruginosa
(PA) has almost doubled, increasing from 9.6% to 18.1%
[2], and PA is the most frequently isolated Gram-
negative aerobic bacterium from ICUs in a US national
large-scale survey (23%) and the most frequent
bacterium isolated from the respiratory tract (32%) [3].
PA-VAP is associated with a high mortality ranging from
40% up to 69% [4–7] and with rates of recurrence more
than 30% despite adequate antimicrobial therapy [7–9].
More than 60% of all ICU patients receive antibiotics
during their hospitalization [10]. It is critical to reduce
antibiotic exposure of ICU patients without compromis-
ing patient safety, and in particular without more recur-
rences. Hence, few studies have reported the recurrence
rate according to the antibiotic therapy duration. In a
randomized non-inferiority trial comparing 8 days versus
15 days of antibiotic duration strategies for VAP, the
mortality and recurrence rate 28 days after bronchos-
copy did not significantly differ between groups [9].
However, patients with VAP caused by non-fermenting
Gram-negative bacilli (NF-GNB), including PA, had a
higher rate of recurrence with short-duration (SD) ther-
apy compared to a long-duration (LD) therapy group
[9]. These results have led the American Thoracic
Society to recommend SD therapy for VAP, with the ex-
ception of VAP with NF-GNB, including Pseudomonas
aeruginosa (PA-VAP) [11]. Nevertheless, many trials
have shown that decreased antibiotic duration for PA-
VAP would be safe and not associated with more recur-
rences or increased mortality [12, 13]. Hence, in a multi-
centric, randomized, controlled trial (the ProVAP study),
an antibiotics discontinuation strategy according to
serum procalcitonin concentrations allowed antibiotic
exposure to be reduced without increasing recurrences
or mortality, even though PA was the most frequently
isolated bacterium [14]. Recently, duration of adequate
antibiotic therapy was found to be not associated with
treatment failure in a retrospective cohort of patients
with PA-VAP [7]. Moreover, three trials [15–17] and a
Cochrane meta-analysis [18] failed to demonstrate that a
short fixed-course (7 or 8 days) antibiotic therapy could
be associated with an increase in mortality or recurrence
rate for patients with a pneumonia documented with PA
or other NF-GNB. Finally, a recent meta-analysis con-
cluded that the two strategies did not differ in terms of
28 day mortality, but because of lack of power, these
conclusions remain a matter of debate [19].
Thus, whereas SD therapy strategy has shown its
efficacy and safety in patients with VAP non-caused byNF-GNB, allowing decreasing antibiotic exposure without
excess morbidity or mortality, its use in patients with doc-
umented VAP of NF-GNB remains a matter of debate.
The impact of the duration of antibiotics on clinical events
in patients with Pseudomonas aeruginosa ventilator-
associated pneumonia (iDIAPASON) study was thus de-
signed to evaluate this important clinical issue.
Methods/design
The study is a randomized, open-labeled non-inferiority
trial comparing two parallel groups: those receiving 8 days
of antibiotic therapy (short duration, SD) and those receiv-
ing 15 days of antibiotic therapy (long duration, LD).
Study population
Patients aged ≥18 years, diagnosed with ventilator-
associated pneumonia documented with Pseudomonas
aeruginosa (PA-VAP), affiliated to French social security,
and providing a written informed consent signed by them-
selves or their next of kin are eligible for inclusion. The
diagnosis of PA-VAP will include a clinical suspicion (≥
two criteria including fever > 38.5 °C, leukocytosis > 109/L
or leukopenia < 4.108/L, purulent tracheobronchial secre-
tions, and a new or persistent infiltrate on chest radiog-
raphy) and confirmation by a Pseudomonas aeruginosa
positive quantitative culture of a respiratory sample: bron-
choalveolar lavage fluid (significant threshold ≥104
colony-forming units (CFU)/mL) or plugged telescopic
catheter (significant threshold ≥103 CFU/mL) or quantita-
tive endotracheal aspirate distal pulmonary secretion sam-
ples (significant threshold ≥106 CFU/mL) [20].
Patients are not eligible in case of the following condi-
tions: pregnancy, immunosuppression (HIV, immuno-
suppressive therapy, corticosteroids >0.5 mg/kg per day
for more than a month), current antibiotic therapy active
on PA for extrapulmonary infection, procedure of
withdrawing life-sustaining treatment, chronic pulmonary
colonization with Pseudomonas aeruginosa (chronic ob-
structive pulmonary disease (COPD) or bronchiectasis, with
a positive respiratory sample below the threshold rate for
Pseudomonas aeruginosa (i.e., <103 CFU/mL for protected
specimen brush or <106 CFU/mL for tracheal aspirate), ob-
tained in the absence of pneumonia or exacerbation during
the 6 months before the ICU admission).
Antibiotic treatment should be started just after
realization of bacteriological sampling, without waiting
for the result. The choice of initial antibiotic therapy will
be left to the discretion of the physician according to
usual care based on the clinical context, previous anti-
biotic therapy, the presence or absence of risk factors for
multidrug-resistant (MDR) pathogen antibiotics or
hospitalization in the previous 90 days (current
hospitalization ≥5 days, mechanical ventilation ≥5 days,
support in a dialysis center or residency in a nursing
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that the patient is already known as being colonized by a
MDR pathogen. In these situations, a broad-spectrum
antibiotic will be recommended immediately, with the
association of a β-lactam/β-lactamase inhibitor or an
antipseudomonal cephalosporin, and an aminoglycoside
or an antipseudomonal fluoroquinolone for 3 to 5 days.
An initial antibiotic with a narrow spectrum will be ac-
cepted in the face of early onset pneumonia (mechanical
ventilation <5 days) and in the absence of risk factors for
MDR pathogens and in accordance to the marketing
authorization (AMM), contraindications, dosing recom-
mendations, and drug interactions (http://base-donnees-
publique.medicaments.gouv.fr/). Investigators are strongly
encouraged to convert this initial regimen into a narrow-
spectrum therapy, based on culture results. All antibiotics
would be withdrawn, either at the end of day 8 or day 15,Fig. 1 Conduct of the study. Study protocol flowchart. SAPS 2: Simplified a
CPIS: clinical pulmonary infection scoreaccording to the randomization assignment, except those
prescribed for a documented pulmonary infection recur-
rence or a new extrapulmonary infection before that day.
The patient will be randomized just after antibiotic sus-
ceptibility test results and assigned to the SD arm or the
LD arm. Screening of MDR pathogens will be realized
with a surveillance culture of swab samples from the rec-
tum for extended-spectrum β-lactam-producing Entero-
bacteriaceae (ESBL) and of swab samples from the
anterior nares for methicillin-resistant Staphylococcus aur-
eus (MRSA) at the patient’s admission in the ICU, and
then once weekly until the patient’s discharge from the
ICU (see Figs. 1 and 2).
Partners
Dr. Adrien Bouglé, coordinating investigator, Hôpital




























Inclusion and non-inclusion criteria X
Written informed consent X




Short-Duration group: end of antibiotic treatment X
Long-Duration group: end of antibiotic treatment X
Assessment:




Procalcitonin X X X X
Leucocytes count X
Mechanical ventilation status X X X




SOFA X X X X X
CPIS X X X X X
Vital status X X
Adverse events X X X X X X X X
Fig. 2 Template of recommended content for the schedule of enrollment, interventions, and assessment. SAPS 2: simplified acute physiology
score (SAPS II); SOFA: sequential organ failure assessment (SOFA) score; CPIS: clinical pulmonary infection score
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and the methodological support will be provided by the
Clinical Research Unit Est (Pr. Tabassome Simon, Hôpi-
tal Saint Antoine, APHP, Paris, France). A steering com-
mittee includes the coordinating investigator, the
scientific director, nine French ICU experts, and the
head of the Clinical Research Unit (see Table 1 for the
composition and affiliations of the members of the steer-
ing committee). This committee will control the proper
conduct of the trial in terms of methodological, ethical,
and logistical aspects.
The study will be performed in 39 French adult ICUs
(Table 1). This work is supported by institutional grants
from the French 2014 Programme Hospitalier de Recherche
Clinique National (PHRC P140923 – AOM14515). The
study is sponsored by the Clinical Research and Develop-
ment Department of Assistance Publique – Hôpitaux de
Paris. The sponsor had no role in the study design, collec-
tion, management, analysis, or interpretation of data, writing
of the report, or the decision to submit the report for publi-
cation. The total duration of the study will be 27 months, in-
cluding the inclusion period (24 months) and the duration
of participation per patient (90 days).
Objectives
The primary objective will be to assess the non-
inferiority of a short duration of antibiotics (8 days)
compared to prolonged antibiotic therapy (15 days) in
Pseudomonas aeruginosa ventilator-associated pneumo-
nia (PA-VAP) on morbidity-mortality at 90 days.The secondary objectives will be to compare between
short and long durations of antibiotics regarding:
– Mortality in the ICU
– Morbidity in the ICU (mechanical ventilation,
duration of hospitalization)
– Exposure and acquisition of MDR pathogens during
hospitalization
– Number and types of extrapulmonary infections
Assessment criteria
The primary assessment criterion will be a composite
endpoint combining day 90 mortality and PA-VAP
recurrence rate during hospitalization in the ICU
(within 90 days). Recurrence will be defined with a
post hoc analysis by two independent experts with
predefined criteria: clinical suspicion of VAP (≥ two
criteria including: fever >38.5 °C, leukocytosis >109/L
or leukopenia <4.108/L, purulent tracheobronchial
secretions, and a new or persistent infiltrate on chest
radiography) associated with a positive quantitative
culture of a respiratory sample (bronchoalveolar
lavage fluid (significant threshold ≥104 CFU/mL),
plugged telescopic catheter (significant threshold
≥103 CFU/mL), or quantitative endotracheal aspirate
distal pulmonary secretion samples (significant thresh-
old ≥106 CFU/mL)). In cases of disagreement between
the two experts, a third expert will reach a consensus.
Thereby, the percentage of patients with PA-VAP
recurrence and/or death will be assessed.
Table 1 Investigators and centers
Investigators Centers
Coordinating Investigator
BOUGLÉ Adrien CHU La Pitié-Salpêtrière, Paris
Scientific Director
AMOUR Julien CHU La Pitié-Salpêtrière, Paris
Co-investigators
BOUGLÉ Adrien CHU La Pitié-Salpêtrière, Paris
MAYAUX Julien CHU La Pitié-Salpêtrière, Paris
LESCOT Thomas CHU Saint Antoine, Paris
LANGERON Olivier CHU La Pitié-Salpêtrière, Paris
POETE Pascale CHU La Pitié-Salpêtrière, Paris
OUATTARA Alexandre CHU Bordeaux
BELLENFANT ZEGDI Florence Hôpital Européen Georges
Pompidou, Paris
CHOLLEY Bernard Hôpital Européen Georges
Pompidou, Paris
PAUGAM Catherine CHU Beaujon, Paris
MONTRAVERS Philippe CHU Bichat, Paris
DURANTEAU Jacques CHU Bicêtre, Paris
COUSSON Joël CHU Reims
DUPONT Hervé CHU Amiens
GARNIER Marc Hôpital Tenon, Paris
LEONE Marc Hôpital Nord, Marseille
GEERAERTS Thomas CHU Toulouse
LEFRANT Jean-Yves CHU Nîmes
VEBER Benoit CHU Rouen
GUICHON Céline Hôpital Croix Rousse, Lyon
SQUARA Pierre Clinique Ambroise Paré,
Neuilly-sur-Seine
LASOCKI Sigismond CHU Angers
MIRA Jean-Paul Hôpital Cochin, Paris
BAUDEL Jean-Luc Hôpital Saint-Antoine, Paris
PAYEN Jean-François CHU Grenoble
KIPNIS Eric CHRU Lille
POTTECHER Julien CHRU Strasbourg
LEGRAND Matthieu Groupe Hospitalier
Lariboisière – Saint Louis, Paris
TESNIERE Antoine Hôpital Cochin, Paris
CONSTANTIN Jean-Michel CHU Clermont-Ferrand
PERTEK Jean-Pierre CHU Nancy Brabois
PICARD Walter CH Pau
FEDERICI Laura CH Sud Francilien,
Corbeil-Essonnes
LEVY Bruno CHU Nancy Brabois
RABBAT Antoine Hôpital Cochin, Paris
LEVESQUE Eric Hôpital Henri Mondor, Créteil
MONGARDON Nicolas Hôpital Henri Mondor, Créteil
Table 1 Investigators and centers (Continued)
CONIA Alexandre CH Chartres
HISSEM Tarik CH Sud Essonne, Étampes
FAURE Henri CHI Robert Ballanger,
Aulnay-Sous-Bois
Steering Committee
BOUGLÉ Adrien (chair) CHU La Pitié-Salpêtrière, Paris
AMOUR Julien CHU La Pitié-Salpêtrière, Paris
SIMON Tabassome URC-Est, Paris
KALFON Pierre CH Chartres
FOUCRIER Arnaud CHU Beaujon, Paris
DUPONT Hervé CHU Amiens
CHOLLEY Bernard Hôpital Européen Georges
Pompidou, Paris
CONSTANTIN Jean-Michel CHU Clermont-Ferrand
LEONE Marc Hôpital Nord, Marseille
MONTRAVERS Philippe CHU Bichat, Paris
OUATTARA Alexandre CHU Bordeaux
SQUARA Pierre Clinique Ambroise Paré,
Neuilly-sur-Seine
VEBER Benoit CHU Rouen
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90 day mortality rate, PA-VAP recurrence rate, mechan-
ical ventilation (MV)-free days, ICU-free days,
antibiotic-free days during the hospitalization in the
ICU, number and types of extrapulmonary infections
during the hospitalization in the ICU, and acquisition of
MDR pathogens during the hospitalization in the ICU
(from swab sample of rectum and anterior nares).Data collection
All efficacy parameters will be collected during
hospitalization of the patient in the ICU. In case of hos-
pital discharge, phone calls will be made by the investi-
gators or the research team with at least three attempts
to contact the patient, his/her physician, or the patient’s
emergency contact in a period of 10 days at different
times of the day. If there is no answer, vital statistics will
be collected via contact of the town council of the pa-
tient’s birthplace.
Data will be collected by the investigators and their
teams in an electronic case report form (e-CRF). Data
will be monitored by a clinical research associate (CRA)
and checked for consistency and missing values by a
data manager.Randomization
Centralized blocked-balanced randomization, in a 1:1 ra-
tio, will be computer-generated by the clinical research
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center. Investigators are blinded to the block size.
Statistical analysis
The study is designed to demonstrate the non-inferiority
on the composite endpoint of mortality and recurrence
at 90 days of the 8-day strategy versus the 15-day strat-
egy for PA-VAP. Considering the mortality and/or recur-
rence of PA-VAP rate of 35.7% [7], 284 patients will be
required in each group to achieve a power of 80% to ex-
clude a 10% difference between the two groups with an
α risk of 5%. To account for a possible 5% patient loss to
follow-up, we planned to enroll 600 patients.
Data analysis
Baseline characteristics of patients will be described per
group. Qualitative data will be described with frequencies
and percentages; quantitative data will be described with
mean and standard error or with median, interquartile
interval, and range. Since this is a non-inferiority study,
analysis of principal criteria will be performed on a per
protocol population. The per protocol population will be
defined as randomized patients without major protocol
deviations such as non-respect of all selection criteria,
clear non-respect of the antibiotic duration allocated (+/–
24 hours), missing data for the primary endpoint, and
major protocol deviation(s) identified during a blinded
data review before data base freezing. Non-inferiority will
be tested by a Dunnett and Gent chi-squared procedure
[21]. Secondary analysis in an intent-to-treat (ITT)
population will also be performed.
Secondary outcomes will be analyzed under a super-
iority assumption. Day 30 and day 90 mortality rates and
acquisition of MDR pathogens during hospitalization in
the ICU will also be compared between groups by a chi-
squared test or a Fisher’s exact test, if the use conditions
were not verified. Duration of mechanical ventilation,
duration of hospitalization in the ICU, duration of
exposure to antibiotics, and number of extrapulmonary
infections during hospitalization in the ICU will be
compared between groups by Student t tests or Mann-
Whitney/Wilcoxon tests, if needed. Types of extrapul-
monary infections will be described.
The association between respiratory colonization with
yeast at diagnosis and PA recurrence will be studied by
logistic regression adjusted on the randomization group.
The association between monotherapy or combination
therapy and mortality and PA recurrence will be studied
by a logistic regression adjusted on the randomization
group. Procalcitonin levels at days 0, 1, 3, and 7 will be
described, and their prognosis values on mortality and P.
aeruginosa recurrence will be studied by logistic regres-
sion and sensitivity and specificity analyses. Missing data
will be not replaced.The study will be conducted in accordance with the
Helsinki Declaration and French laws and regulations.
The study has received its approval from the French
ethics committee (Comité de Protection des Personnes
Ile de France VI) as well from the French Drug Safety
Agency (Agence Nationale de Sécurité du Médicament
et des Produits de Santé) (EudraCT 2015-003102-17).
All records and subjects’ identities will remain
confidential in accordance with the following French
regulations: the French National Committee of Inform-
atics and Liberties and the French Consultative Commit-
tee for Data Processing in Health Research rules. The
trial protocol was written following the Recommenda-
tions for Interventional trials (SPIRIT) Checklist (see
Additional file 1).
Discussion
This study will investigate the influence of duration of
antibiotic therapy on mortality and recurrence of PA-VAP.
Our goal is to demonstrate that a short antibiotic therapy
(8 days of effective antibiotic therapy) compared to a long
antibiotic therapy (15 days of effective antibiotic therapy)
is safe without excess mortality or recurrence, and de-
creases the duration of exposure to antibiotics and the ac-
quisition of MDR pathogens. Furthermore, this study will
evaluate the relationship between PA recurrence and (1)
respiratory colonization with yeast at diagnosis, (2) treat-
ment with monotherapy or combination therapy, and (3)
procalcitonin levels during the course of VAP.
We believe that the present study has several strengths.
First, it specifically addresses the issue of recurrence of
PA-VAP, and the number of patients to be included (n =
600) has been calculated according to an expected rate of
35% for the composite endpoint combining 90 day mor-
tality and PA-VAP recurrence as shown in a previous
study [7]. This expected rate is in accordance with
previously published data. Hence, Combes et al. reported
a recurrence rate of 28% [22]. In a meta-analysis, the fre-
quency of VAP recurrence was 26.8%. Acute lung injury/
acute respiratory distress syndrome and shock on the day
of diagnosis of the first VAP episode, but not the first-
episode causative pathogens, were found to be associated
with VAP recurrence [23]. Finally, in the cohort published
by Planquette et al. on 314 patients with 393 PA-VAP, fail-
ure occurred for 112 of them (35.7%), including 79 recur-
rences (20.1%) [7].
Crouch Brewer et al. reported in a cohort of 38 con-
secutive PA-VAP a mortality of 69% with an attributable
mortality of 38% [4]. We can emphasize that persistent
pneumonia occurred in 35% of patients while recurrence
of pneumonia was unusual (1/38). Trouillet at al. re-
ported a cohort of 135 PA-VAP. In this cohort, 70 pa-
tients (52%) died during the ICU stay, and only 10
patients had recurrences [5]. Finally, in a retrospective,
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five Spanish ICUs, Garnacho-Montero et al. reported
183 monomicrobial episodes of PA-VAP, with a mortality
of 42.1% [6], and an Italian retrospective analysis of data
prospectively collected about 110 cases of PA-VAP and
reported an ICU mortality of 44.5% [24].
The study is open-labeled, because a double-blind
study would have presented considerable financial and
organizational constraints. Thus, we cannot completely
rule out the risk of bias, especially the non-compliance
with the antibiotic therapy duration. Nevertheless, first,
investigators received clear instructions about the crucial
importance of compliance with the treatment allocation.
Second, the comparison of the duration of exposure to
antibiotics between groups and between centers will give
us an indication about non-compliance with study arms.
Third, post hoc analysis of the primary endpoint will be
conducted without any knowledge of the study arm.
In conclusion, this study should contribute to deter-
mine the most appropriate duration of antibiotic therapy
treatment in the specific case of PA-VAP to decrease
both mortality and the recurrence rate of PA-VAP. If
our hypothesis is confirmed, the study may lead to de-
creased antibiotic exposure during the hospitalization in
ICU and in turn reduce the acquisition and the spread
of MDR. The therapeutic perspectives which could re-
sult from this study are thus promising.
Trial status
The first patients were randomized in June 2016. The in-
clusion of participants is ongoing and is expected to
continue until June 2018.
Additional file
Additional file 1: SPIRIT checklist. (DOC 147 kb)
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COPD: Chronic obstructive pulmonary disease; ICU: Intensive care unit;
MDR: Multidrug-resistant (pathogens); PA: Pseudomonas aeruginosa;
PCT: Procalcitonin; VAP: Ventilator-associated pneumonia
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